What question did this study set out to answer?

To evaluate a two-component vaccine that combines an adenoviral vector and a subunit protein to enhance immune responses against the SARS-CoV-2 Omicron variant.

March 14, 2026Molecular BiomedicineOpen Access

Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant

View Full Paper

Ask AI

Bookmark

Authors

CYChunjun YeSichuan University XHXiya HuangSichuan University WHWeiqi HongSichuan University

Discussion

Member takes

Implication

Combination vaccine elicits robust immune response in mice, indicating adaptability for future variants.

Key Points

To evaluate a two-component vaccine that combines an adenoviral vector and a subunit protein to enhance immune responses against the SARS-CoV-2 Omicron variant.
Developed a two-component vaccine consisting of an adenoviral vector and self-assembling trimeric receptor-binding domain protein.
Administered vaccine intramuscularly in mice.
Evaluated humoral and cellular immunity responses over six months post-immunization.
Assessed the vaccine as a heterologous booster following mRNA vaccine priming.
The combination vaccine elicited robust IgG responses in mice that lasted over six months.
The vaccine effectively generated memory B cells and long-lived plasma cells.
Served as a successful booster after mRNA priming, enhancing neutralization against emerging variants.

Cite This Study

Ye et al. (2026) studied this question.

synapsesocial.com/papers/69b4fbd5b39f7826a300c401 https://doi.org/10.1186/s43556-026-00410-x

View Full Paper

Ask AI

Bookmark

March 14, 2026Molecular BiomedicineOpen Access

Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant

View Full Paper

Ask AI

Bookmark

Authors

CYChunjun YeSichuan University XHXiya HuangSichuan University WHWeiqi HongSichuan University

Discussion

Member takes

Implication

Combination vaccine elicits robust immune response in mice, indicating adaptability for future variants.

Key Points

To evaluate a two-component vaccine that combines an adenoviral vector and a subunit protein to enhance immune responses against the SARS-CoV-2 Omicron variant.
Developed a two-component vaccine consisting of an adenoviral vector and self-assembling trimeric receptor-binding domain protein.
Administered vaccine intramuscularly in mice.
Evaluated humoral and cellular immunity responses over six months post-immunization.
Assessed the vaccine as a heterologous booster following mRNA vaccine priming.
The combination vaccine elicited robust IgG responses in mice that lasted over six months.
The vaccine effectively generated memory B cells and long-lived plasma cells.
Served as a successful booster after mRNA priming, enhancing neutralization against emerging variants.

Cite This Study

Ye et al. (2026) studied this question.

synapsesocial.com/papers/69b4fbd5b39f7826a300c401 https://doi.org/10.1186/s43556-026-00410-x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark